# Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations

> **NCT07664839** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shen yang** · enrollment: 148 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- NPM1 Mutation
- IDH1 Mutation
- IDH2 Mutation

## Interventions

- **DRUG:** VEN combined with azacitidine
- **DRUG:** Cytarabine plus Daunorubicin

## Key facts

- **NCT ID:** NCT07664839
- **Lead sponsor:** Shen yang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2028-05-31
- **Final completion:** 2032-05-31
- **Target enrollment:** 148 (ESTIMATED)
- **Last updated:** 2026-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07664839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07664839, "Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07664839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*